Fulgent Genetics (FLGT) Notes Payables (2021 - 2026)

Fulgent Genetics has disclosed Notes Payables across 6 years of filings, most recently posting $482000.0 for Q1 2026.

• Notes Payables for Q1 2026 came in at $482000.0, up 1.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $482000.0 (up 1.26% YoY), and the FY2025 annual result was $476000.0, up 15.53% from the prior year.
• Notes Payables came in at $482000.0 for Q1 2026 at Fulgent Genetics, up from $476000.0 in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $6.1 million in Q1 2022 to a low of $412000.0 in Q2 2024.
• The 5-year median for Notes Payables is $482000.0 (2026), against an average of $2.4 million.
• Across the five-year window, Notes Payables sank 92.64% in 2024 and gained 15.53% in 2025, its largest moves.
• Fulgent Genetics' Notes Payables stood at $5.6 million in 2022, then sank by 79.02% to $1.2 million in 2023, then slumped by 65.17% to $412000.0 in 2024, then grew by 15.53% to $476000.0 in 2025, then increased by 1.26% to $482000.0 in 2026.
• The last three Notes Payables figures came in at $482000.0 (Q1 2026), $476000.0 (Q4 2025), and $476000.0 (Q3 2025), per Business Quant data.